4 results about "Estrogenic drug" patented technology

This application discloses a compound, its preparation method, pharmaceutical composition, and application, belonging to the field of pharmaceutical synthesis and application technology. The compound is selected from formula (I) or formula (II). This compound can improve oral bioavailability, enabling oral administration and solving a series of problems associated with injecting fulvestrant in clinical practice. In vivo, it can be metabolized to produce fulvestrant and can inhibit / degrade estrogen receptor prodrug molecules, treating estrogen receptor-related diseases.

A targeted chimeric compound, a pharmaceutical composition containing the same, and its preparation method and use. The targeted chimeric compound is represented by general formula (I), and the substituents in general formula (I) have the same definitions as in the specification. Compared with fulvestrant in the prior art, the targeted chimeric compound has comparable or even superior antiproliferative activity against mutation-resistant cells of estrogen receptor α, and is thus expected to exhibit comparable or even superior therapeutic efficacy.

The present invention relates to a pharmaceutical composition comprising fulvestrant and a method for preparing the same, and more particularly, to a pharmaceutical composition comprising fulvestrant as a poorly soluble drug, a nonionic surfactant, castor oil and a specific alcohol, and a method for preparing the same, the fulvestrant preparation does not contain lecithin or the content of lecithin is less than a specific content, so that the fulvestrant preparation has excellent pharmacokinetic characteristics, and has the same pharmacological treatment effect as that of the conventional fulvestrant preparation.

A fulvestrant pharmaceutical composition, a preparation method therefor, and an application thereof are provided. The fulvestrant pharmaceutical composition contains fulvestrant solid particles. The particle size of the fulvestrant solid particles satisfies that Dv(10) is selected from 0.400 micrometers to 6.000 micrometers, Dv(50) is selected from 0.700 micrometers to 6.000 micrometers, and Dv(90) is selected from 1.000 micrometers to 6.000 micrometers, provided that Dv(10) is not 0.400 micrometers, Dv(50) is not 0.700 micrometers, and Dv(90) is not 1.000 micrometers. The fulvestrant pharmaceutical composition has a long-acting sustained release.